Actively Recruiting
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease
Led by Central Hospital, Nancy, France · Updated on 2026-02-03
240
Participants Needed
2
Research Sites
6 weeks
Total Duration
On this page
Sponsors
C
Central Hospital, Nancy, France
Lead Sponsor
C
Centre Hospitalier Régional Metz-Thionville
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the gut microbiota, serum cytokines, and peripheral blood mononuclear cells (PBMC) in patients with Crohn's disease (CD) alone, spondyloarthritis (SpA) alone, both conditions, and healthy controls. The goal is to identify differences in the fecal microbiota through bacteriome, virome, and fungome sequencing. This project aims to better understand the biological markers associated with these diseases and their overlap. Participants are divided into four groups: those with Crohn's disease without spondyloarthritis, those with spondyloarthritis without Crohn's disease, those with both conditions, and healthy individuals. Stool samples will be collected for next-generation sequencing (NGS) to analyze the diversity of bacteria, viruses, and fungi present in the gut. This process focuses on detailed microbiota profiling without involving drug treatments. During the study, researchers will measure the alpha and beta diversity of fecal bacteriome, fungome, and virome at baseline and after six months. Participants will provide stool samples and undergo clinical assessments. The study involves monitoring these biological markers over time to observe changes or patterns associated with the presence of Crohn's disease, spondyloarthritis, or both. The total duration for participants includes follow-up at six months for outcome measurement.
CONDITIONS
Brief Title
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Patients with Crohn's disease and axial spondyloarthritis
- Patients with Crohn's disease diagnosed by clinical, biological, radiological, endoscopic, or histological studies for at least 3 months, excluding spondyloarthritis
- Patients with axial spondyloarthritis diagnosed by modified ASAS or New York criteria, excluding Crohn's disease
- Ability to give informed consent
You will not qualify if you...
- History of colonic resection
- Use of antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection
- Presence of ostomy at the time of sampling
- Body mass index (BMI) greater than 30
- Extreme diet
- Unbalanced diabetes
- Pregnancy
- Under guardianship, curatorship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants are observed to identify fecal microbiota biomarkers related to spondyloarthritis and Crohn's disease.
1 visit at baseline and 1 follow-up visit at 6 months
Trial Site Locations
Total: 2 locations
1
Central Hospital
Nancy, Lorraine, France, 54500
Actively Recruiting
2
Saint Antoine Hospital
Paris, France, 75012
Actively Recruiting
Research Team
L
Laurent MD PEYRIN-BIROULET, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here